Deltex Medical Group plc (DTXMF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Deltex Medical Group plc (DTXMF) with AI Score 51/100 (Hold). Deltex Medical Group plc specializes in oesophageal Doppler haemodynamic monitoring systems. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Deltex Medical Group plc (DTXMF) Healthcare & Pipeline Overview
Deltex Medical Group plc provides haemodynamic monitoring solutions, primarily through its TrueVue Doppler system, used in critical care and surgical settings. The company focuses on optimizing fluid management and blood flow in patients, operating within the competitive medical devices market, with a global presence in the UK, US, Spain, and Canada.
Investment Thesis
Deltex Medical Group plc presents a focused investment opportunity within the haemodynamic monitoring sector. The company's TrueVue system addresses a critical need for precise fluid management in surgical and critical care settings. While the company's negative P/E ratio of -0.22 and profit margin of -72.2% indicate current challenges, the 63.3% gross margin suggests potential for profitability with increased sales and cost management. Growth catalysts include expanding adoption of TrueVue in the US market and potential partnerships with larger medical device companies. Key risks include competition from established players and the need for continued innovation to maintain market relevance. The company's beta of -2.55 suggests a low correlation with the overall market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.18 billion indicates the company's current valuation in the market.
- Negative P/E ratio of -0.22 reflects current unprofitability, suggesting potential for future earnings growth.
- Gross margin of 63.3% demonstrates the company's ability to generate revenue above the cost of goods sold.
- Beta of -2.55 indicates a negative correlation with the market, suggesting potential stability during market downturns.
- The company operates internationally, with a presence in the UK, US, Spain, and Canada, providing geographic diversification.
Competitors & Peers
Strengths
- Proprietary TrueVue oesophageal Doppler technology.
- Established presence in key markets (UK, US, Spain, Canada).
- Specialized product portfolio focused on haemodynamic monitoring.
- High gross margin (63.3%) indicates pricing power.
Weaknesses
- Negative profit margin (-72.2%) indicates profitability challenges.
- Small employee base (24) may limit scalability.
- Reliance on a single product line (TrueVue).
- OTC market listing may limit investor access.
Catalysts
- Ongoing: Expansion of TrueVue adoption in US hospitals and surgical centers.
- Ongoing: Strategic partnerships with medical device distributors.
- Ongoing: Development of new haemodynamic monitoring technologies.
- Ongoing: Integration of TrueVue data with EHR systems.
Risks
- Potential: Increased competition from established medical device companies.
- Potential: Technological obsolescence of TrueVue technology.
- Potential: Regulatory changes affecting medical device approvals.
- Potential: Economic downturns impacting hospital budgets.
- Ongoing: Negative profit margin and profitability challenges.
Growth Opportunities
- Expansion in the US Market: Deltex Medical has a significant opportunity to expand its presence in the US market. The US medical device market is one of the largest in the world, with a growing demand for advanced haemodynamic monitoring technologies. By increasing its sales and marketing efforts in the US, Deltex Medical can capitalize on this demand and drive revenue growth. This expansion could be accelerated through strategic partnerships with US-based distributors or healthcare providers. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: Deltex Medical can pursue strategic partnerships or acquisitions to expand its product portfolio and market reach. Collaborating with complementary medical device companies or acquiring smaller players with innovative technologies can enhance Deltex Medical's competitive position and accelerate growth. These partnerships could provide access to new markets, technologies, or distribution channels. Timeline: Ongoing.
- Product Innovation and Development: Continued investment in research and development is crucial for Deltex Medical to maintain its competitive edge. By developing new and improved haemodynamic monitoring technologies, the company can address unmet clinical needs and attract new customers. This includes exploring non-invasive monitoring solutions and integrating its technology with other medical devices. Timeline: Ongoing.
- Adoption in Emerging Markets: Deltex Medical can explore opportunities to expand its presence in emerging markets, where there is a growing demand for advanced medical technologies. These markets often have less stringent regulatory requirements and lower competitive intensity, providing a favorable environment for growth. However, it is important to carefully assess the market dynamics and regulatory landscape before entering these markets. Timeline: Ongoing.
- Integration with Electronic Health Records (EHR) Systems: Integrating Deltex Medical's haemodynamic monitoring data with EHR systems can enhance the value proposition for healthcare providers. This integration would allow clinicians to access real-time patient data and make more informed decisions. It would also streamline the workflow and reduce the risk of errors. Timeline: Ongoing.
Opportunities
- Expansion in the US market.
- Strategic partnerships and acquisitions.
- Product innovation and development.
- Adoption in emerging markets.
Threats
- Competition from established medical device companies.
- Technological obsolescence.
- Regulatory changes.
- Economic downturns affecting hospital budgets.
Competitive Advantages
- Proprietary oesophageal Doppler technology.
- Established brand reputation in haemodynamic monitoring.
- Specialized product portfolio focused on fluid management.
- Global distribution network.
About DTXMF
Deltex Medical Group plc, established in 2000 and headquartered in Chichester, UK, develops, manufactures, and markets haemodynamic monitoring systems. Its flagship product, the TrueVue oesophageal Doppler monitoring (ODM) system, provides real-time blood flow and fluid status measurements. This technology assists clinicians in optimizing fluid management during surgery and in critical care settings. The company's product line includes esophageal Doppler Probes, Loops, High Definition Impedance Cardiography, PressureWave, and the Deltex Medical Esophageal Doppler Simulator. These products are utilized in a range of medical procedures, including major abdominal, laparoscopic, and spinal surgeries, cardiac, trauma, and transplant procedures, as well as in the management of conditions like sepsis and post-operative acute kidney injury. Deltex Medical distributes its products in the United Kingdom, the United States, Spain, and Canada, as well as internationally. Deltex Medical's focus on precision fluid management positions it within the broader medical devices market, catering to the needs of hospitals and surgical centers seeking to improve patient outcomes and reduce complications related to fluid imbalances.
What They Do
- Manufactures oesophageal doppler haemodynamic monitoring systems.
- Markets TrueVue monitoring systems globally.
- Sells esophageal Doppler Probes for real-time blood flow measurement.
- Offers Loops for aortic blood flow and blood pressure monitoring.
- Provides High Definition Impedance Cardiography for non-invasive cardiac monitoring.
- Develops PressureWave algorithm for pulse pressure waveform analysis.
- Supplies Deltex Medical Esophageal Doppler Simulator for training.
Business Model
- Direct sales of TrueVue haemodynamic monitoring systems.
- Recurring revenue from the sale of disposable esophageal Doppler Probes.
- Service and maintenance contracts for installed monitoring systems.
- Training and education programs for clinicians on the use of their products.
Industry Context
Deltex Medical Group plc operates within the medical devices industry, specifically focusing on haemodynamic monitoring. The market is characterized by technological advancements and increasing demand for minimally invasive and precise monitoring solutions. Key trends include the growing adoption of advanced monitoring technologies in critical care and surgical settings, driven by the need to improve patient outcomes and reduce complications. The competitive landscape includes companies like ACRDF (Accuray Incorporated), BLMHF (Bellerophon Therapeutics Inc), DOCRF (Second Sight Medical Products Inc), FFLWF (Fluidigm Corporation), and PXMVF (Proximus NV), each offering various monitoring solutions. Deltex Medical differentiates itself through its unique oesophageal Doppler technology and focus on fluid management.
Key Customers
- Hospitals and surgical centers.
- Critical care units.
- Anesthesiologists and surgeons.
- Medical professionals involved in fluid management during surgery and critical care.
Financials
Chart & Info
Deltex Medical Group plc (DTXMF) stock price: Price data unavailable
Latest News
No recent news available for DTXMF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DTXMF.
Price Targets
Wall Street price target analysis for DTXMF.
MoonshotScore
What does this score mean?
The MoonshotScore rates DTXMF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Natalie Emilia Wettler
Managing Director
Natalie Emilia Wettler serves as the Managing Director of Deltex Medical Group plc. Information regarding her detailed career history and educational background is not available in the provided data. However, as Managing Director, she is responsible for overseeing the company's strategic direction and day-to-day operations.
Track Record: Due to limited information, specific achievements and milestones under Natalie Emilia Wettler's leadership cannot be detailed. However, as Managing Director, she is responsible for guiding the company's growth and profitability.
DTXMF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Deltex Medical Group plc may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and performance. Investing in companies on the OTC Other tier carries higher risks compared to those listed on major exchanges like the NYSE or NASDAQ due to the potential for less transparency and regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure due to OTC Other tier status.
- Lower liquidity and potential for wider bid-ask spreads.
- Higher price volatility compared to major exchanges.
- Potential for less regulatory oversight and investor protection.
- Increased risk of fraud or manipulation.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's growth prospects and potential risks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal disputes involving the company.
- Understand the risks associated with investing in OTC stocks.
- Established operations in the UK, US, Spain, and Canada.
- Proprietary TrueVue technology.
- Presence in the haemodynamic monitoring market.
- Gross margin of 63.3% suggests a viable business model.
- Incorporated in 2000 indicates a history of operations.
What Investors Ask About Deltex Medical Group plc (DTXMF)
What does Deltex Medical Group plc do?
Deltex Medical Group plc specializes in haemodynamic monitoring solutions, primarily through its TrueVue system. This system utilizes oesophageal Doppler technology to measure a patient's central vascular blood flow and fluid status in real-time. The company's products are used in various surgical and critical care settings to optimize fluid management, improve patient outcomes, and reduce complications related to fluid imbalances. Deltex Medical operates in the global medical devices market, with a focus on precision fluid management.
What do analysts say about DTXMF stock?
As of 2026-03-16, there is no available analyst consensus on DTXMF stock. Key valuation metrics include a negative P/E ratio of -0.22 and a market capitalization of $0.18 billion. The company's gross margin of 63.3% suggests potential for profitability with increased sales and cost management. Growth considerations include expanding adoption of TrueVue in the US market and potential partnerships with larger medical device companies. Investors should conduct their own due diligence before making any investment decisions.
What are the main risks for DTXMF?
Deltex Medical Group plc faces several risks, including competition from established medical device companies, the potential for technological obsolescence of its TrueVue technology, and regulatory changes affecting medical device approvals. The company's negative profit margin and profitability challenges also pose a significant risk. Additionally, economic downturns could impact hospital budgets and reduce demand for its products. As an OTC-listed company, DTXMF faces additional risks related to liquidity and transparency.
What are the key factors to evaluate for DTXMF?
Deltex Medical Group plc (DTXMF) currently holds an AI score of 51/100, indicating moderate score. Key strength: Proprietary TrueVue oesophageal Doppler technology.. Primary risk to monitor: Potential: Increased competition from established medical device companies.. This is not financial advice.
How frequently does DTXMF data refresh on this page?
DTXMF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven DTXMF's recent stock price performance?
Recent price movement in Deltex Medical Group plc (DTXMF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary TrueVue oesophageal Doppler technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider DTXMF overvalued or undervalued right now?
Determining whether Deltex Medical Group plc (DTXMF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying DTXMF?
Before investing in Deltex Medical Group plc (DTXMF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-16.
- OTC market data may be limited or delayed.
- AI analysis pending for DTXMF.